Adalimumab biosimilars launches in Europe.
An overview of adalimumab biosimilar progress in Europe.- Imraldi from Samsung Bioepis has launched in major markets in Europe. Amgevita from Amgen has launched in markets across Europe. Cytelzo from Boehringer will not yet launch in Europe as the company is involved in patent litigation with AbbVie in the US. Hyrimoz from Novartis is launched in the UK with other EU markets to follow. Hulio from Mylan is intended to be launched in the EU "before or after 16 October 2018". Pricing varies from country to country. Humira is better protected by patents in the US than in Europe.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.